Peptide Therapy
Fundamentals
A comprehensive 1.5-day intensive that builds the complete clinical foundation for prescribing peptide therapy. Day 1 covers peptide science fundamentals — mechanism of action, receptor specificity, physiological vs supraphysiological dosing — then moves into the core peptide protocols: GH secretagogues (CJC-1295/Ipamorelin, Sermorelin, Tesamorelin, MK-677), metabolic peptides (Semaglutide, Tirzepatide, Retatrutide, AOD 9604), and recovery peptides (BPC-157, TB-500). Day 2 morning completes the course with lab-guided patient assessment, goal-based protocol selection, subcutaneous injection technique, compounding pharmacy relationships, pricing your peptide program, and practice launch infrastructure. You leave ready to see peptide patients on Monday.
Questions? Call 480-447-8166 or email [email protected]
Ask about the Fundamentals + Advanced bundle — save $600.
What you learn over
1.5 days with Naomi
Peptide therapy is not a menu of products — it's a clinical discipline that requires understanding of receptor biology, physiological dosing, lab-guided patient assessment, regulatory compliance, and practice infrastructure. This 1.5-day program is structured to take you from peptide science fundamentals to day-one clinical practice.
Day 1 builds the scientific foundation and covers the three core peptide categories: GH secretagogues (CJC-1295/Ipamorelin, Sermorelin, Tesamorelin, MK-677), metabolic and weight management peptides (Semaglutide, Tirzepatide, Retatrutide, AOD 9604), and recovery peptides (BPC-157, TB-500). Each category is taught with mechanism of action, dosing protocols, patient selection, lab monitoring, and side effect management.
Day 2 morning completes the course: lab-guided patient assessment, goal-based protocol selection, subcutaneous injection technique and patient training, compounding pharmacy evaluation, peptide pricing strategy, and the consultation workflow that turns this training into a functioning peptide service line.
- What peptides are: short-chain amino acid signaling molecules (2–50 amino acids) that bind specific receptors to trigger targeted biological responses — distinct from hormones in mechanism, side effect profile, and regulatory classification
- Signaling vs. replacing: how GH secretagogues stimulate your pituitary to produce its own growth hormone in physiological pulsatile patterns — preserving feedback loops that exogenous HGH bypasses entirely
- Receptor specificity: CJC-1295 binds GHRH receptors exclusively, PT-141 binds melanocortin-4 receptors, GHK-Cu modulates collagen gene expression in fibroblasts — this precision is what makes peptides safer than broad-acting hormones
- Physiological vs. supraphysiological dosing: the clinical principle of restoring IGF-1 to optimal range, not exceeding it — why lab-guided dosing is the safety and efficacy standard
- Subcutaneous delivery pharmacokinetics: why most therapeutic peptides bypass oral administration, insulin needle technique, absorption profiles, and patient self-injection training methodology
- Peptide stability, reconstitution, and storage: bacteriostatic water, refrigeration requirements, and shelf life considerations that affect clinical practice
- The FDA regulatory framework for peptide therapy: which peptides are FDA-approved (semaglutide, tirzepatide, PT-141), which are compounded under 503A/503B pharmacy rules, and the clinical and legal distinction
- 503A vs. 503B compounding pharmacies: what each license means, what quality controls each requires, and why this matters for your prescribing liability
- The FDA's evolving position on compounded peptides: the semaglutide/tirzepatide compounding controversy, shortage designations, and how to stay compliant as the landscape shifts
- Off-label prescribing: the legal framework for prescribing FDA-approved drugs off-label vs. prescribing compounded peptides — documentation requirements for each
- PCAB accreditation: what it means, how to verify it, and why sourcing from a PCAB-accredited pharmacy is the baseline quality standard
- DEA considerations: which peptide-adjacent compounds (testosterone, controlled substances) require DEA registration and which do not — the compliance distinction
- State-specific prescribing: Arizona NP full practice authority for peptide prescribing, PA collaborative agreement considerations, and RN standing order requirements
- The GH/IGF-1 axis review: pituitary somatotroph cells, pulsatile GH secretion, liver IGF-1 production, and the physiological effects on body composition, sleep, skin, and recovery
- CJC-1295 with DAC vs. without DAC + Ipamorelin: the most commonly prescribed GH secretagogue combination — mechanism (GHRH receptor + ghrelin receptor dual stimulation), dosing protocol, injection timing (bedtime for sleep-phase GH pulse), and clinical expectations at 6–12 weeks
- Sermorelin: the GHRH analog with the longest clinical track record — dosing, half-life considerations, comparison to CJC-1295/Ipamorelin, and patient selection criteria
- Tesamorelin: the FDA-approved GHRH analog (HIV lipodystrophy) — its uniquely potent effect on visceral adipose tissue, off-label use for body composition and metabolic optimization, and the regulatory distinction from other secretagogues
- MK-677 (Ibutamoren): the oral ghrelin receptor agonist — the convenience advantage for patients who resist injection, dosing, the insulin resistance concern that requires baseline metabolic screening, and the patient conversation about oral vs. injectable options
- IGF-1 target ranges: how to interpret baseline IGF-1, set a physiological target (upper quartile of age-adjusted normal), dose-titrate to target, and monitor — with specific lab timing guidance
- Side effects and monitoring: water retention in early therapy (self-limiting), vivid dreams, tingling, and the active malignancy contraindication — the screening and documentation protocol
- Semaglutide (GLP-1 receptor agonist): mechanism of action — appetite suppression via hypothalamic signaling, delayed gastric emptying, insulin sensitization — dosing titration schedule, the branded vs. compounded landscape, and the clinical expectations at 12–16 weeks
- Tirzepatide (dual GLP-1/GIP agonist): the dual-incretin advantage — why GIP receptor activation adds body composition benefits beyond GLP-1 alone, dosing protocol, and comparison to semaglutide for specific patient profiles
- Retatrutide (triple agonist — GLP-1/GIP/glucagon): the emerging triple agonist — mechanism, clinical trial data summary, patient selection, and where this fits in the treatment algorithm relative to semaglutide and tirzepatide
- AOD 9604: the GH fragment peptide for lipolysis — mechanism (mimics the fat-metabolizing fragment of HGH without IGF-1 elevation), dosing, and its positioning as a non-appetite-suppressing metabolic tool
- Tesamorelin for visceral fat: how Tesamorelin's selective visceral adipose reduction complements GLP-1 therapy — the combination protocol rationale and lab monitoring
- GI side effects management: nausea, constipation, and the dose-titration approach that minimizes discontinuation — plus the rare but serious gallbladder and pancreatitis risk screening
- The metabolic patient assessment: baseline labs (fasting insulin, HbA1c, lipid panel, CMP), BMI vs. waist-to-height ratio, and the protocol selection decision tree
- BPC-157 (Body Protection Compound-157): a gastric pentadecapeptide with documented tissue repair properties — mechanism of action (angiogenesis, nitric oxide modulation, growth factor upregulation), injectable vs. oral forms, and the clinical evidence base
- TB-500 (Thymosin Beta-4): mechanism (actin-binding, cell migration, anti-inflammatory) — how it complements BPC-157's angiogenic mechanism for comprehensive tissue repair
- The Wolverine Stack (BPC-157 + TB-500): the most commonly prescribed recovery combination — synergy rationale, combined dosing protocol, 4–8 week typical duration, and the clinical scenarios where this stack produces the best results (tendon/ligament injury, post-surgical recovery, chronic tendinopathy, athletic overuse)
- Injectable BPC-157 dosing: systemic vs. local injection, the perilesional injection technique for localized injury, and how to determine which approach for each patient presentation
- Oral BPC-157 for GI applications: dosing for IBS, leaky gut, and gastric healing — the gut-specific delivery rationale and how oral BPC-157 fits into a comprehensive gut healing protocol
- Contraindications and safety: the current evidence base limitations, the active cancer concern with any angiogenic peptide, and the documentation standards for prescribing recovery peptides
- The peptide patient intake: the structured consultation framework — symptom inventory, goal prioritization (fat loss, muscle, recovery, longevity, cognitive, libido, gut, immune, hair/skin), and health history screening
- Baseline lab panels by protocol category: IGF-1 for GH secretagogues, fasting insulin + HbA1c for metabolic peptides, CMP for hepatic/renal function screening, CBC, thyroid panel, testosterone/DHEA-S/estradiol for hormonal context, ferritin/zinc/vitamin D for hair/skin protocols
- Contraindication screening: active malignancy (GH secretagogues), uncontrolled diabetes (GH axis protocols), pregnancy, pacemaker considerations — the systematic checklist before any prescription
- Goal-to-protocol matching: a decision framework that maps patient goals to specific peptide protocols — using Beso's 12-protocol model as the clinical template (GH optimization, muscle building, weight loss, recovery, longevity, immune, gut, endocrine, hair/skin, libido, cognitive, stacking)
- Setting patient expectations: response timelines by protocol category (GH secretagogues 6–12 weeks, recovery peptides 4–8 weeks, GLP-1 agents 12–16 weeks), the importance of compliance, and managing patients who expect immediate results
- Monitoring and follow-up: IGF-1 recheck at 6–8 weeks for GH protocols, metabolic markers for weight management, and the documentation workflow that supports safe long-term peptide management
- Subcutaneous injection technique for providers: proper needle selection (insulin syringe, 29–31 gauge), injection site selection (abdomen, thigh), angle of insertion, aspiration considerations, and post-injection site management
- Teaching patients to self-inject: the patient education sequence — demonstration, guided practice, observation — and the take-home instruction materials that reduce call-backs and anxiety
- Reconstitution technique: bacteriostatic water, proper vial handling, drawing the correct volume, and the math for concentration calculation (total mcg per vial ÷ mL of BAC water = mcg per 0.1mL)
- Multi-peptide injection logistics: which peptides can be drawn together, timing of different peptides (bedtime vs. morning), and the patient-friendly schedule that maximizes compliance
- Needle anxiety management: the techniques that reduce injection fear in needle-phobic patients — this is a surprisingly common barrier to peptide therapy adoption
- Intranasal and oral troche alternatives: which peptides have non-injectable delivery options (Semax, Selank, BPC-157 oral), when to use them, and the bioavailability trade-offs
- Compounding pharmacy evaluation: PCAB accreditation, COA (certificate of analysis) review, sterility testing documentation, beyond-use dating practices, and how to evaluate a pharmacy before placing your first order
- Building your formulary: which peptides to start with (the “starter 5” for a new peptide practice — CJC-1295/Ipamorelin, BPC-157, Semaglutide, Tesamorelin, TB-500), and how to expand over time as clinical volume justifies
- Peptide pricing strategy: cost-of-goods for common peptides, markup models (2.5–4x COGS is typical), monthly patient pricing by protocol ($200–$600/month range for most protocols), and the membership vs. per-visit pricing decision
- Stack pricing: how to price multi-peptide protocols — the discounted bundle approach vs. à la carte pricing, and the revenue math for each model
- Documentation and consent: the peptide-specific informed consent template — covering off-label use, compounding pharmacy sourcing, expected timeline, side effects, and the lab monitoring schedule
- Medical director requirements: how peptide prescribing fits into Arizona's regulatory framework for NPs (full practice authority), PAs (collaborative agreement), and RNs (standing orders from medical director)
- The peptide consultation workflow: from initial inquiry to labs to consultation to prescription to follow-up — the step-by-step process that turns a training course into a functioning peptide service line
Built for providers who want
clinical peptide fluency
You already understand the endocrine system and lab-guided prescribing. Peptide therapy is the natural extension — adding targeted biological signaling tools to your existing clinical toolkit. This course bridges the gap between hormone prescribing and peptide-specific protocol design.
Peptide therapy is one of the highest-margin services in integrative medicine. Monthly peptide patients generate $200–$600/month in recurring revenue with low consumable costs. This course gives you the clinical foundation and business infrastructure to launch a peptide program.
Patient demand for peptide therapy is surging — driven by social media, longevity influencers, and GLP-1 awareness. Providers who can't have the peptide conversation are losing patients to online peptide clinics. This course makes you the expert your patients are looking for.
If you're already prescribing semaglutide or tirzepatide for weight management, you've seen the power of targeted peptide therapy. This course expands your repertoire from GLP-1 agents into GH secretagogues, recovery peptides, and the complete metabolic optimization toolkit.
Active unrestricted clinical licensure. No prior peptide therapy experience required — the course starts from peptide science fundamentals and builds to clinical practice. Providers with existing hormone optimization experience will find the GH axis content builds directly on that foundation.
- MD / DO — active, unrestricted license
- Nurse Practitioner (NP/FNP) — active, unrestricted license
- Physician Assistant (PA-C) — active, unrestricted license
- RN — active license + medical director standing order
- Full 1.5-day didactic instruction with Naomi
- Comprehensive peptide dosing reference guide for all protocols covered
- Lab panel interpretation guide — baseline and monitoring panels by protocol category
- Patient intake form and peptide consultation template
- Goal-to-protocol decision framework
- Consent forms for GH secretagogues, GLP-1 agents, and recovery peptides
- Subcutaneous injection technique training materials and patient handouts
- Compounding pharmacy evaluation checklist
- Peptide pricing calculator and membership model template
- Certificate of Completion from Beso Provider Hub
- Lunch and refreshments both days
Lab-guided, not
sales-driven
Many peptide courses are sponsored by compounding pharmacies or online peptide companies. They're good at teaching you about their products. They're less focused on teaching you which patients should not receive peptides, how to interpret labs that suggest a different intervention, or how to price a peptide program that sustains a practice. Their incentive is product volume.
Naomi's course is built from running a peptide therapy program at Beso Wellness & Beauty. The protocols, the dosing, the lab interpretation, the patient conversations — all of it reflects what she has learned managing real peptide patients, including patients who didn't respond to standard protocols and patients who needed a different clinical approach entirely.
The A4M peptide certification costs $5,500 for two modules. This course covers comparable clinical depth for the protocols most commonly prescribed in outpatient practice — at a fraction of the cost, in person, with the business infrastructure to launch immediately.
Every protocol taught in this course is drawn from Naomi's clinical practice at Beso Wellness & Beauty — the same dosing, the same lab panels, the same patient assessment framework she uses with her own patients.
No peptide is prescribed at Beso without baseline labs. This course teaches the same discipline: IGF-1 before GH secretagogues, metabolic panels before GLP-1 agents, contraindication screening before every protocol.
Most peptide courses skip pricing, compounding pharmacy relationships, and practice infrastructure. This one doesn't. You leave with pricing templates, a compounding pharmacy evaluation checklist, and the consultation workflow to start seeing patients.
The Fundamentals course builds the foundation. The Peptides Advanced course (1 additional day, or $5,800 bundled) adds longevity, immune, cognitive, libido, gut peptides, and the multi-protocol stacking discipline. Together they create the most comprehensive peptide training outside of a fellowship.
Common questions
Meet Naomi
Naomi Fayzulayev, FNP-C
Founder, Beso Wellness & Beauty · Board-Certified Family Nurse PractitionerNaomi founded Beso Wellness and Beauty to close the gap between clinical training and real-world practice — offering the kind of hands-on, small-group instruction she wished she had when she started. With over 15 years of clinical experience and deep roots in regenerative and aesthetic medicine, she brings active, practicing expertise to every course she teaches.
Her approach is integrative: combining conventional medicine with evidence-based wellness therapies to address root causes, not symptoms. As a Certified Trainer for the Cellular Medicine Association (CMA), Naomi personally trains other medical providers in advanced procedures including the O-Shot® and P-Shot® — a credential held by a small number of practitioners nationally. She holds advanced certifications in functional medicine, hormone optimization, and advanced medical aesthetics, and is known for her meticulous technique and the warm, patient-centered environment she creates in every training session.
She believes a well-trained provider is the foundation of a well-run practice. Every course she teaches reflects that: small cohorts, live patients, real feedback, and the business context to use the skills you leave with.
Clinical Practice
Per Cohort
Trainer
Active Practice
1.5 days to a
peptide practice
The Peptide Therapy Fundamentals course is $3,800 — 1.5 days, 8 comprehensive modules, 30+ peptides covered, a complete documentation library, and a Certificate of Completion. Bundle with the Peptides Advanced course for $5,800 (save $600). Space is limited — cohort size is kept small deliberately so every attendee has direct access to Naomi.
Inquire & Enroll →